{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-201161","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.125983+00:00","generated_at":"2026-06-12T12:57:55.971205+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Karyopharm Q2 total rev $37.6M; net loss $32.6M; cuts workforce 20%, guides FY rev $145-160M","bullets":["Q2 total rev $37.6M (down 5% YoY); net loss $32.6M ($0.29/sh) improved from $49.1M ($0.62/sh).","U.S. XPOVIO net product rev $28.5M (flat YoY); FY 2023 guidance: total rev $145-160M, XPOVIO $110-125M.","Workforce cut ~20%; non-GAAP R&D+SG&A guidance lowered to $240-255M; cash runway extended into late 2025.","Initiated pivotal Phase 3 (XPORT-MF-034) of selinexor+ruxolitinib in JAKi-naïve myelofibrosis; Fast Track from FDA.","Revenue Interest Financing amended: cap raised to 195%, warrants for 250k shares at $2.25, payment date extended to June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-201161","json":"https://secwatch.observer/filing/0001193125-23-201161.json","markdown":"https://secwatch.observer/filing/0001193125-23-201161.md","text":"https://secwatch.observer/filing/0001193125-23-201161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/0001193125-23-201161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/d542880d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:57:55.971205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a89922f95db2fd09cf15522668898cff963a3be","claim":"Karyopharm Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $37.6 Million. Guidance reaffirmed.","evidence_excerpt":"Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress – Achieved Second Quarter 2023 Total Revenue of $37.6 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/0001193125-23-201161-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$37.6 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}